AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Abbott protease inhibitor shines in combinations.
The HIV protease inhibitor ritonavir (ABT-538) nearly obliterated HIV in some patients who took the drug in combination with two standard AIDS therapies.
Moreover, animal studies show that ritonavir in combination with another protease inhibitor, saquinavir, overcomes pharmacologic barriers to that drug and packs an intense one-two punch against HIV.
Researcher Daniel Norbeck of Abbott Laboratories, which manufactures ritonavir, announced preliminary results of a clinical trial of ritonavir combination therapy at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 17-20, 1995, in San Francisco, California.
Trial …
-
- AMPRENAVIR (Oral route) - am-PREN-a-veer.(Drug overview)
-
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language
May 1, 2007
700+ words
-
- Expanded options for HIV treatment on horizon. (Improved Convenience, Lower...
-
Magazine article from: Family Practice News
Finn, Robert
March 1, 2003
700+ words
-
- Prophylaxis after occupational exposure to HIV: recent guidelines should...
-
Magazine article from: British Medical Journal
Easterbrook, Philippa Ippolito, Giuseppe
September 6, 1997
700+ words
-
- SAQUINAVIR (Oral route) - sa-KWIN-a-veer.(Drug overview)
-
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language
May 1, 2007
700+ words
-
- FOSAMPRENAVIR (Oral route) - FOS-am-pren-a-veer.(Drug overview)
-
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language
May 1, 2007
700+ words
